Cefoxitin
From Wikipedia, the free encyclopedia
 |
|
|
Cefoxitin
|
|
| Systematic (IUPAC) name | |
| (6S,7R)-4-(carbamoyloxymethyl)-7-methoxy- 8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C16H17N3O7S2 |
| Mol. mass | 427.454 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | minimal |
| Half life | 41-59 min |
| Excretion | 85% urine |
| Therapeutic considerations | |
| Pregnancy cat. |
B |
| Legal status | |
| Routes | IV |
Cefoxitin is a cephamycin antibiotic developed by Merck & Co., Inc., often grouped with the second−generation cephalosporins. It is also known as Mefoxin.
[edit] Microbiology
Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes. It is inactive in vitro to most strains of Pseudomonas aeruginosa and enterococci and many strains of Enterobacter cloacae. Staphlococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin. [1]
[edit] References
|
||||||||||||||||||||
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
